Waters (WAT) Stock Rises On Revenue Surge While Losses Cloud Earnings
Waters (NYSE:WAT) shares rose about 6% after Q2 revenue jumped to $1.645 billion, including $817 million from the BD Biosciences and Diagnostic Solutions acquisition. GAAP results showed a net loss of $136 million and basic EPS loss of $1.38, while free cash flow was $202 million. Organic revenue grew 7% reported and 9% constant currency.
How this was made
The 30-second read
Why it matters
The quarter shows strong top-line growth and positive free cash flow despite a GAAP EPS loss, creating a split between revenue momentum and earnings quality.
Market read
Traders are repricing the stock on acquisition-fueled revenue growth, while still discounting the durability of earnings and margin improvement.
What to watch
The article flags flat EBIT margin guidance and reliance on $200M run-rate cost savings; traders may want to focus on whether organic growth (7% reported, 9% constant currency) can persist without further accounting noise.
Background
Waters is integrating newly acquired BD Biosciences and Diagnostic Solutions into its analytical workflow platform.
Ticker impact
Waters shares jumped about 6% as Q2 revenue surged to $1.645B, with the BD Biosciences and Diagnostic Solutions acquisition contributing $817M.
Likely continued volatility as traders weigh revenue momentum versus persistent GAAP earnings pressure and margin/cost-savings execution.
The article cites a same-day ~6% move tied to the quarter’s revenue surge and acquisition contribution, but also highlights a GAAP EPS loss ($1.38 to $1.39) and flat EBIT margin guidance, leaving integration durability as the key debate.
Market effects
Signals that life-sciences instrument demand and workflow installed-base strength can offset acquisition-related earnings noise, but margin execution remains a watch item for the group.
No specific regional catalyst beyond the US-listed name’s earnings reaction.
Limited, as the piece is company-specific and does not describe broader industry/regulatory shifts.
Counterpoint
The revenue beat may be acquisition-driven and not yet translated into sustainable GAAP profitability, so the stock move could fade if integration costs and interest expense keep GAAP EPS negative.
Key entities
- public_companyWaters
NYSE-listed life sciences instruments and analytical workflow solutions provider, subject of the article’s earnings reaction.
- acquired_businessBD Biosciences and Diagnostic Solutions
Acquired units contributing $817M of the quarter’s $1.645B revenue, central to the bull case and integration debate.
